What is the experimental breast cancer vaccine targeting?

The experimental vaccine targets a protein called a-lactalbumin, which is produced by about 70 percent of triple-negative breast cancers.

How effective were the Phase 1 trials for the experimental vaccine?

In Phase 1 trials, 74 percent of women developed an immune response to the vaccine, and it was found to be safe with no serious adverse effects.

When will the experimental breast cancer vaccine be available?

The experimental vaccine is still years away from being made available to patients as it is advancing through Phase 2 trials.

Home / Health / Cancer Survivor's Hope: Experimental Vaccine Trial Success

Cancer Survivor's Hope: Experimental Vaccine Trial Success

5 Feb

•

Summary

Chase Johnson, 36, received an experimental vaccine after beating aggressive breast cancer.
The vaccine targets a protein common in 70% of triple-negative breast cancers.
Phase 1 trials showed the vaccine to be safe, with 74% developing an immune response.

Cancer Survivor's Hope: Experimental Vaccine Trial Success

Chase Johnson, now 36, a North Carolina attorney, has remained cancer-free since undergoing treatment for aggressive triple-negative breast cancer diagnosed in February 2021. Her journey included chemotherapy, surgery, and radiation.

Facing a high risk of recurrence, Johnson sought further options and participated in a Phase 1 trial for an experimental breast cancer vaccine in December 2022. This vaccine targets a protein present in about 70% of triple-negative breast cancers.

The initial Phase 1 trials, involving 35 women like Johnson, demonstrated the vaccine's safety. Researchers observed that 74% of participants developed an immune response, with only minor side effects like localized swelling and fever.